Article

Diabetic retinopathy risks studied

Interesting new findings have emerged from a study of the risk factors for the development and progression of diabetic retinopathy, namely, that its severity determines the rate of progression, especially in younger patients.

Novel factors, such as younger age and an interrelationship with macular edema, were newly identified, and ethnicity may be an independent risk factor for progression of retinopathy and macular edema. Colin Tan, MBBS, MMed(Ophth), FRCSEd, presented the study findings during the annual meeting of the American Society of Cataract and Refractive Surgery.

"Diabetic retinopathy is the major cause of visual impairment and blindness worldwide," said Dr. Tan, consultant, Department of Ophthalmology, Tan Tock Seng Hospital, National Healthcare Group Eye Institute, Singapore.

"One reason for this may be the interrelationships among the various risk factors," he explained.

In light of these discrepancies, Dr. Tan and colleagues studied patients with the disease over the course of 5 years as well as the risk factors associated with different facets of the disease: pre-existing diabetic retinopathy, the development and rate of progression of diabetic retinopathy, and development of clinically relevant diabetic macular edema.

A total of 250 patients (mean age, 66 years) (500 eyes) with type 2 diabetes were included and followed for more than 5 years. Patients with coexisting ocular pathologies or a history of ocular surgeries were excluded. The diabetic retinopathy was graded using the Early Treatment of Diabetic Retinopathy Study classification. The results underwent univariate and multivariate analyses.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.